Cellular senescence in cancer treatment: friend or foe?

Tools

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
589kB

Item Type:	Article
Title:	Cellular senescence in cancer treatment: friend or foe?
Creators Name:	Kahlem, P., Doerken, B. and Schmitt, C.A.
Abstract:	Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
Keywords:	Antineoplastic Agents, Apoptosis, Cell Aging, Tumor Cell Line, Cyclin-Dependent Kinase Inhibitor p16, DNA, DNA Damage, Biological Models, Neoplasms, Tumor Suppressor Protein p53, Animals
Source:	Journal of Clinical Investigation
ISSN:	0021-9738
Publisher:	American Society for Clinical Investigation
Volume:	113
Number:	2
Page Range:	169-174
Date:	January 2004
Official Publication:	https://doi.org/10.1172/JCI20784
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year